GlobeNewsWire
31 May 2026, 23:30 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/31/3303966/0/en/Ascentage-Pharma-Presents-Updated-Clinical-Data-for-Olverembatinib-as-Second-Line-Therapy-in-CML-CP-at-ASCO-2026.html
Read source
Story key points
4 claims · impact-rated
Updated clinical data for olverembatinib in CML-CP showed a 91.3% complete cytogenetic response (CCyR) and 60.9% major molecular response (MMR) rate at cycle 24. — Strong efficacy data in a high-visibility venue (ASCO) typically drives positive sentiment for biotech stocks and validates the drug's clinical profile.
+0.60Ascentage Pharma is conducting three global registrational Phase III studies for olverembatinib, with two cleared by the FDA and EMA. — Phase III progression and regulatory clearance in major markets (US/EU) significantly increase the probability of future revenue growth and commercial scalability.
+0.50The company has an exclusive option agreement with Takeda for the global rights to develop and commercialize olverembatinib outside of Greater China. — Potential partnership with a global giant like Takeda reduces financial risk and provides a clear path to international market penetration.
+0.40Continue reading
6 related stories
Search tags
Olverembatinib has a manageable safety profile with no new safety signals identified during long-term treatment. — Confirmation of safety is a prerequisite for regulatory approval and market adoption, removing a major potential risk factor.
+0.30Ticker attribution
Model heads
The company presented positive updated efficacy and safety data for olverembatinib at ASCO 2026.
The company presented positive updated efficacy and safety data for olverembatinib at ASCO 2026.
Innovent is jointly commercializing olverembatinib in China, benefiting from the positive clinical data.
Takeda holds an exclusive option agreement to license and commercialize olverembatinib globally outside of Greater China.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
